Novartis Sues Par Over Dementia Patch Generic

Law360, New York (August 23, 2013, 3:14 PM ET) -- Novartis AG hit rival Par Pharmaceutical Inc. with a suit in Delaware federal court Thursday, accusing Par’s proposed generic version of dementia treatment Exelon of infringing a patent covering the drug.

According to the Swiss pharmaceutical giant, Woodcliff Lake, N.J.-based Par’s planned 13.3-milligram generic rivastigmine transdermal patches infringes upon U.S. Patent Number 6,335,031, a patent jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG.

“There is a substantial and immediate controversy between plaintiffs and Par concerning the '031 patent,” the complaint said....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required